Finance

Lists
Why is PHVS up 3,80%?
Dive Deeper
PHVS:NASDAQ
Pharvaris NV
USD 30,90
+3,80%
(+1,13) 1D
USD 30,90
0,00% (0,00)
After hours
Closed: 20 Okt., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PHVS...
Open
USD 29,83
High
USD 31,60
Low
USD 29,83
Mkt. cap
2,17 mjd
Avg. vol.
1,01 m
Volume
1,03 m
52-wk high
USD 43,25
52-wk low
USD 21,03
EPS
-USD 2,93
Beta
-2,46
Shares outstanding
69,86 m
No. of employees
148
Open
USD 29,83
High
USD 31,60
Low
USD 29,83
Mkt. cap
2,17 mjd
Avg. vol.
1,01 m
Volume
1,03 m
52-wk high
USD 43,25
52-wk low
USD 21,03
EPS
-USD 2,93
Beta
-2,46
Shares outstanding
69,86 m
No. of employees
148
News stories
From web sources and news partners
About Pharvaris NV
CEO-
Employees148
Founded2015
Headquarters-
SectorPharmaceutical industry
Analyst ratings
Based on 12 analysts giving stock ratings to PHVS in the past 3 months
Strong buy
Buy
11
Hold
1
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for PHVS in the last 3 months.
Highest
Current USD 30,90
USD 79,00 (+155,66%)
Average
USD 61,33 (+98,48%)
Lowest
USD 44,00 (+42,39%)
Analyst
Recommendation
Action
Price target
Projected
Date
Maxwell Skor
Morgan Stanley
Buy
Reiterated
USD 62,00
+100,6%
10/19/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
USD 65,00
+110,4%
10/15/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
USD 60,00
+94,2%
10/06/2026
Debjit Chattopadhyay
Guggenheim
Buy
Maintained
USD 44,00
+42,4%
09/09/2026
Steven Seedhouse
Cantor Fitzgerald
Buy
Reiterated
USD 65,00
+110,4%
09/09/2026
Laura Chico
Wedbush
Buy
Maintained
USD 50,00
+61,8%
09/09/2026
Joseph Schwartz
Leerink Partners
Buy
Reiterated
USD 65,00
+110,4%
09/10/2026
Nevin Varghese
RBC Capital
Buy
Maintained
USD 62,00
+100,6%
09/09/2026
Debanjana Chatterjee
JonesTrading
Buy
Reiterated
USD 65,00
+110,4%
09/09/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
USD 79,00
+155,7%
09/09/2026
Tazeen Ahmad
Bank of America Securities
Hold
Reiterated
USD 44,00
+42,4%
09/08/2026
Justin Kim
Oppenheimer
Buy
Maintained
USD 75,00
+142,7%
09/08/2026
Jeff Jones
Oppenheimer
Buy
Maintained
USD 75,00
+142,7%
09/08/2026
Unknown Analyst
Oppenheimer
Buy
Reiterated
USD 50,00
+61,8%
08/13/2026
Unknown Analyst
Guggenheim
Buy
Maintained
USD 40,00
+29,4%
08/12/2026
Andy Chen
Wolfe Research
Buy
Initiated
USD 42,00
+35,9%
04/08/2026
Unknown Analyst
RBC Capital
Buy
Initiated
USD 52,00
+68,3%
03/09/2026
Last report
12 Aug. 2026
Fiscal period
Q2 2026
-€0,70 / -€0,65
-7,09%miss
Revenue / Est. (EUR)
- / 0,00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
29,81 m
34,14 m
30,16 m
35,00 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9,85 m
13,46 m
14,11 m
15,79 m
Operating expense
39,66 m
47,60 m
44,27 m
50,79 m
Total operating expenses
39,66 m
47,60 m
44,27 m
50,79 m
Operating income
-39,66 m
-47,60 m
-44,27 m
-50,79 m
Other non operating income
-
-
-86,40 k
-72,60 k
EBT including unusual items
-37,32 m
-45,08 m
-38,93 m
-47,24 m
EBT excluding unusual items
-37,32 m
-45,08 m
-38,93 m
-47,24 m
Income tax expense
-181,47 k
1,66 m
273,11 k
602,20 k
Effective tax rate
0,49%
-3,69%
-0,70%
-1,27%
Other operating expenses
-
-
-
-
Net income
-37,14 m
-46,74 m
-39,20 m
-47,84 m
Net profit margin
-
-
-
-
Earnings per share
-0,60
-0,71
-0,60
-0,70
Interest and investment income
2,15 m
2,19 m
1,67 m
1,98 m
Interest expense
-50,03 k
-58,74 k
-
-
Net interest expenses
2,10 m
2,13 m
1,67 m
1,98 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-39,62 m
-47,55 m
-44,22 m
-50,66 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google-programme